Giotrif (afatinib dimaleate): Reviews and patient testimonials
Medication indications
Giotrif 20 mg/30 mg/40 mg/50 mg film-coated tablets
GIOTRIF as monotherapy is indicated for the treatment of
• Epidermal Growth Factor Receptor (EGFR) TKI-naïve adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s);
• locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum-based chemotherapy.
Route of administration: Oral
Molecule: afatinib dimaleate
Patients' opinions on Giotrif
In brief
General satisfaction level: 1.00/10 Learn more
Treatment's effectiveness: 1.00/10 Learn more
Ease of use: 1.00/10 Learn more
Adherence to prescription: 1.00/10 Learn more
Detected side effects: 1.00/10 Learn more
Improvement in the quality of life: Be the first to evaluate
1 = Not at all satisfied
10 = Extremely satisfied
1 = Not at all satisfied
10 = Extremely satisfied
1 = Not at all satisfied
10 = Extremely satisfied
1 = Never
10 = Always
1 = Not at all important
10 = Extremely important
1 = Not at all satisfied
10 = Extremely satisfied
Tips and advice of the community